MedTrace Logo

TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

NCT05496569 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-11-21

No results posted yet for this study

Summary

A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.

Conditions

  • Dedifferentiated Liposarcoma

Interventions

DRUG

TQB3616 capsule

TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor

DRUG

TQB3616 placebo

Placebo

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-08
Primary Completion
2024-06-15
Completion
2025-09-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05496569 on ClinicalTrials.gov